share_log

BeiGene Shares Are Trading Higher After the European Commission on Tuesday Approved Tislelizumab for Non-small Cell Lung Cancer Across Three Indications, Including First- and Second-line Use.

BeiGene Shares Are Trading Higher After the European Commission on Tuesday Approved Tislelizumab for Non-small Cell Lung Cancer Across Three Indications, Including First- and Second-line Use.

歐盟委員會週二批准替雷利珠單抗用於三種適應症（包括一線和二線用途）的非小細胞肺癌，此後，百濟神州股價走高。
Benzinga ·  04/24 22:41

BeiGene Shares Are Trading Higher After the European Commission on Tuesday Approved Tislelizumab for Non-small Cell Lung Cancer Across Three Indications, Including First- and Second-line Use.

歐盟委員會週二批准替雷利珠單抗用於三種適應症（包括一線和二線用途）的非小細胞肺癌，此後，百濟神州股價走高。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論